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Abstract: Since there is a high prevalence of type 2 dia-
betes mellitus (DM2), as well as CVD in Montenegro, we 
aimed to estimate CVD risk by United Kingdom Prospec-
tive Diabetes Study (UKPDS) risk engine algorithm in 
individuals with DM2. Furthermore, we aimed to explore 
whether non-traditional biomarker such as high sensi-
tivity C-reactive protein (hsCRP) is superior for CVD risk 
prediction over old traditional risk factors. A total of 
180 participants with DM2 (of them 50% females) were 
included in the current cross-sectional study. Biochemi-
cal and anthropometric parameters, and blood pressure 
were obtained. More males than females were classified 
at high UKPDS risk category (p<0.001). Also, about one 
third of diabetic patients (29.4%) were classified into the 
high-risk category. In multivariate regression analysis, 
triglycerides [Odds ratio (OR) =1.703, p=0.001] and creati-
nine concentration (OR=1.040, p<0.001) were independent 
predictors of CVD risk, whereas hsCRP was not correlated 
with CVD risk. HsCRP is not superior for CVD risk predic-
tion by UKPDS risk engine algorithm over high triglyceride 
and creatinine levels in diabetic population, which sug-
gests that the old traditional markers must not be under-
estimated when examining CVD risk in population with 
diabetes. 
Keywords: Cardiovascular risk; Type 2 diabetes; UKPDS 
risk engine
1  Introduction
Cardiovascular disease (CVD) represents the major cause 
of death in subjects with type 2 diabetes mellitus (DM2). It 
is estimated that almost three-quarters of individuals with 
DM2 die from CVD [1]. Therefore, assessment of CVD risk is 
of great importance for preventing adverse cardiovascular 
outcomes in this population group. Also, an assessment of 
CVD risk can be a useful tool for prevention of poor treat-
ment of individuals at high-risk, as well as inappropriate 
treatment of subjects at low risk [2].
The CVD risk in DM2 patients has been estimated by 
various algorithms so far. The American College of Cardi-
ology/AmericanHeartAssociation (ACC/AHA) calculator 
for CVD risk enables generation of sex- and race-specific 
risk predictions and also, represents the only US-based 
CVD risk prediction algorithm that has been validated in 
other US-based populations [3].
 However, the two most widely used risk predictions 
in Europe are the Framingham risk score (FRS) and United 
Kingdom Prospective Diabetes Study (UKPDS) risk engine 
[4].
Although the 10-year FRS and ACC/AHA calculator 
include several established parameters, there are varia-
bles that are not included, but which may add significant 
contribution to CVD risk assessment exclusively in partic-
ipants with DM2, such as levels of glycated hemoglobin 
(HbA1c) and duration of diabetes [4].
Furthermore, the UKPDS risk engine was developed 
for a large cohort of almost 5100 specifically newly diag-
nosed patients with DM2, during a median follow-up of 
10.7 years [4], whereas FRS included almost 5580 indi-
viduals, but only 6% of them were known to have DM2. 
Therefore, it is speculated that FRS tended to underesti-
mate risk for people with DM2 [5].
In comparison with Framingham and SCORE (System-
atic Coronary Risk Evaluation) algorithms,  the UKPDS risk 
engine was shown to be more precise in predicting CVD in 
a Hoorn study cohort of newly diagnosed DM2 subjects [6].
In line with this, there are discrepant results obtained 
from many studies, showing that the different CVD risk 
algorithms have variable precision in different popula-
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tions when distinguishing subjects who are at high-risk 
from the other ones [7-12]. Moreover, a weak concordance 
between predicted and actual cardiovascular risk was also 
reported [13]. All these discrepant results may partly be 
explained by the fact that some ethnic groups have higher 
CVD risk than the others [14].
To our knowledge, there are no studies concerning the 
estimation of CVD risk by the UKPDS risk engine algorithm 
in population with DM2 in Montenegro. Even though it is 
a part of Mediterranean basis where Mediterranean diet is 
easily available, there is a high prevalence of DM2 [15], as 
well as CVD [16] in this developing country. Therefore, we 
aimed to estimate CVD risk by UKPDS risk engine in indi-
viduals with DM2. In addition, we sought for the utility of 
non-traditional markers [i.e., high sensitivity C-reactive 
protein (hsCRP)], over traditional ones for the best CVD 
risk prediction.
2  Materials and methods
2.1  Study population
This investigation derived from previous study which 
examined the utility of adiposity indexes in subjects with 
DM2 [17].
The current cross-sectional research included a total 
of 180 patients with DM2 (of them 90 females). The recruit-
ment of participants with DM2 was done in the Primary 
Health Care Center in Podgorica, Montenegro, during their 
visit for laboratory analyses routine checkup in a period 
from October 2015 to May 2016.
The inclusion and exclusion criteria for diabetic par-
ticipants were followed by 2016 American Diabetes Asso-
ciation Standards of Diabetes Care [18]. Subjects that met 
the inclusion criteria were volunteers with previously 
diagnosed DM2 or with at least two fasting plasma glucose 
levels ≥ 7.0 mmol/L, or random plasma glucose level of  ≥ 
11.1 mmol/L.
Participants with fasting glucose ≥ 5.6 mmol/L, but < 
7.0 mmol/L, were asked to undergo oral glucose tolerance 
test (OGTT). Those subjects with plasma glucose level 
≥ 11.1 mmol/L 2 hours after an OGTT were also included 
in the research, as well as those participants with gly-
cosylated hemoglobin (HbA1c)  ≥ 6.5% on two different 
measurements [18]. 
Participants with 2-h postload glucose < 11.1 mmol/L 
were excluded from the study. Also those with: HbA1c < 
6.5%,  type 1 diabetes mellitus, hsCRP > 10 mg/L, hypo-
thyroidism or hyperthyroidism, subjects on chronic dialy-
sis, kidney disease other than diabetic nephropathy, liver 
disease other than steatosis, a recent (6 months) history of 
acute myocardial infarction or stroke, ethanol consump-
tion >20 g/day, usage of anti-inflammatory medications in 
the last 6 months, and pregnancy, were excluded from the 
investigation.
The Institutional Review Board of Primary Health Care 
Center in Podgorica, Montenegro approved the research 
protocol and the study was conducted in accordance with 
the Declaration of Helsinki. Informed consent was signed 
by all subjects that participated in the examination.
Anthropometric measurements were obtained from 
each examinee [i.e., WC (cm), body height (cm), weight 
(kg) and BMI (kg/m2)], as described elsewhere [19].
2.2  Biochemical analyses
The blood samples were collected in a period from 7 to 9 
o’clock in the morning after an overnight fast of at least 
8 hours. Level of HbA1c was determined using immu-
noturbidimetric method (Roche Cobas 400, Mannheim, 
Germany) in a sample of a whole blood in K2EDTA. Serum 
levels of glucose, lipid parameters [i.e., triglycerides (TG), 
total cholesterol (TC), high density lipoprotein cholesterol 
(HDL-c), low density lipoprotein cholesterol (LDL-c)], uric 
acid, and bilirubin, were performed on the same analyzer, 
using spectrophotometric assay. Serum hsCRP levels were 
measured nephelometrically (Behring Nephelometer Ana-
lyzer, Marburg, Germany).
The Modification of Diet in Renal Disease Study equa-
tion (eGFRMDRD) was used for estimation of glomerular fil-
tration rate, as following:
eGFRMDRD (mL/min/1.73 m2) = 186 × [serum creati-
nine (µmol/L) / 88.4]-1.154 × [Age (years)]-0.203 × 0.742 (if 
female) [20].
UKPDS risk engine (ver. 2.0) was calculated, as 
described elsewhere [21].
Variables that entered UKPDS risk engine equation 
were: age, sex, ethnicity, smoking status, atrial fibrilla-
tion status, diabetes duration, HbA1c, systolic BP, TC, and 
HDL-c. All participants were divided into three groups: 
low risk (< 15%), medium risk (≥15% and <30%), and high 
risk category (≥ 30%) [21].
2.3  Statistical analysis
Kolmogorov-Smirnov test was applied for testing the dis-
tribution of variables. Normal Gaussian distributed data 
were shown as mean [standard deviation (SD)] and com-
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pared by one-way analysis of variance with Tukey-Kramer 
post-hoc test. For non-normal distributed data logarith-
mic transformation was performed to achieve normality 
and data were presented as geometric mean [95% Con-
fidence Interval (CI)]. Those data were also compared 
using one-way analysis of variance with Tukey-Kramer 
post-hoc test. If the data were not normally distributed 
even after logarithmic transformation, they were pre-
sented as median (interquartile range) and compared 
using Kruskal-Wallis (three groups’ comparisons) and 
Mann-Whitney (two groups’ comparisons) tests. Chi-
square test was applied for comparison of categorical 
variables that were presented as absolute frequencies. 
Possible correlation between CVD risk score and clinical 
parameters were tested with Spearman’s non-parametric 
correlation analysis and results were given as correlation 
coefficient (ρ). 
A receiver operating characteristic (ROC) curve analy-
sis was applied to reveal clinical markers that could iden-
tify 10-year CVD risk in DM2 population. Area under curve 
(AUC) higher than 0.75 was considered as a good discrim-
ination. The associations between presence of CVD risk 
(low and medium vs. high) and clinical parameters were 
evaluated by logistic regression analysis, adjusted for 
potential confounders which were not used for CVD risk 
calculations, but had clinical relevance to enter analysis.
Two-tailed p<0.05 was used as the criterion for a 
statistically significant differences and correlations. All 
analyses were done using the PASW® Statistic version 22 
(Chicago, Illinois, USA).
3  Results
Table 1 shows distribution of DM2 patients according to 
low, medium and high CVD risk. Males and females were 
not equally distributed in risk categories. Results showed 
that more men than women were classified at high risk 
of UKPDS score. Furthermore, there were significant dif-
ferences in insulin therapy usage in CVD risk categories 
(p=0.009), (Table 1). As it was expected, DM2 patients 
classified at high CVD risk category were older (p<0.001) 
and had DM2 for a longer period of time than those at low 
and medium risk (p<0.001), because ages and duration of 
diabetes entered the equations for risk score calculation.
Beside markers, which were used in risk scores cal-
culations (TC, HDL-c and HBA1c), TG, LDL-c, creatinine, 
and eGFRMDRD were significantly different between low, 
medium and high CVD risk category. The TG levels were 
lower in the low than in the medium and high CVD risk 
category (p<0.01 and p<0.001, respectively). Similarly, 
Table 1: Demographic characteristics of diabetic patients according to CVD risk
Low risk
< 15%
Medium risk
≥15% <30%
High risk
≥ 30% p
N (male/female) 76 (23/53)
51
(26/25)
53
(41/12) <0.001
Age (years) 56.00 (49.50-65.00) 63.00 (58.25-71.00)a,* 69.00 (63.00-77.00) a,b* <0.001
BMI (kg/m2) 30.11 (27.03-36.64) 29.00 (27.15-32.18) 28.67 (26.39-32.01) 0.192
WC (cm) 107.00 (98.00-113.00) 105.00 (99.00-111.00) 105.00 (99.50-113.00) 0.883
SBP (mmHg) 135.00 (130.00-145.00) 130.00 (126.00-140.00) 132.00  (121.50-140.00) 0.155
DBP (mmHg) 80.00 (70.00-86.00) 80.00 (74.25-84.75) 80.00 (70.00-86.00) 0.709
Smoking habits (No/Yes) 59/17 38/13 41/12 0.911
Antihyperglycemics (No/Yes) 10/66 4/47 9/44 0.374
Insulin (No/Yes) 70/6 41/10 38/15 0.009
Hypolipidemics (No/Yes) 47/29 23/28 33/20 0.118
Antihypertensives (No/Yes) 25/51 13/38 13/40 0.507
Duration of diabetes (years) 2.00 (1.00-5.00)
6.00 
(2.00-9.75)a,*
8.00 
(4.00-12.25)a,* <0.001
Data are presented as median (interquartile range) and compared by Kruskal-Wallis test
Smoking habits and drug usage are given as absolute frequencies and compared by Chi-square test
a – significantly different from low risk by Mann-Whitney test
b – significantly different from medium risk by Mann-Whitney test
* p < 0.05
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the lower creatinine concentration was shown in the low 
than in the medium and high CVD risk category (p<0.01), 
(Table 2).
As expected, CVD risk score highly correlated with 
markers which were used in their calculations (age, TC, 
HDL-c, HBA1c), (Table 3). Also, CVD risk values highly 
positively correlated with TG level (p<0.01), creatinine 
concentration (p<0.01) and highly negatively correlated 
with eGFRMDRD (p<0.01).
Multivariate regression analysis was applied in order 
to examine independent predictions of clinical parame-
ters that were significantly different between risk groups 
and that did not enter the equations for risk scores calcu-
lation (TG and creatinine), on CVD risk occurrence (low 
and medium vs. high). The eGFRMDRD was excluded for 
further logistic regression analysis because age was used 
for its calculation, the same as for risk score calculation. 
Multivariate adjustment was made for clinical parameters 
which had clinical relevance to CVD risk (BMI, WC, hsCRP, 
DBP and therapies usage). The TG (OR=1.703, p=0.001) 
and creatinine concentration (OR=1.040, p<0.001) kept 
independent prediction of the occurrence of CVD risk. 
According to R2 obtained in logistic regression analysis, 
the model was able to explain variation in CVD risk by 
31.7% (Table 4).
Table 2: Clinical parameters in diabetic patients according to CVD risk
Low risk
< 15%
Medium risk
≥15% <30%
High risk
≥ 30% p
TC (mmol/L) 5.12±0.97 5.30±0,98 5.78±1.43a† 0.004
HDL-c (mmol/L) 1.34±0.32 1.14±0.30a† 1.01±0.26a‡ <0.001
LDL-c (mmol/L) 3.01±0.87 3.14±0.89 3.74±1.14a‡,b† <0.001
TG (mmol/L)* 1.57 (1.43-1.72) 2.14 (1.87-2.47)a† 2.26 (1.94-2.65)a‡ <0.001
Glucose (mmol/L)** 6.90 (6.00-7.70) 7.20 (6.27-8.47) 8.90 (7.10-11.75)c,d# <0.001
HbA1c (%)** 6.00 (5.50-6.65) 6.70 (5.90-7.90)c# 7.70 (6.60-9.67)c,d† <0.001
Uric acid (µmol/L) 304.62±78.52 306.90±74.76 306.90±74.76 0.958
Total bilirubin (µmol/L)** 6.15 (4.60-8.10) 5.60 (4.12-7.93) 6.15 (4.60-8.10) 0.230
hsCRP (mg/L)** 1.89 (0.99-3.62) 1.30 (0.92-2.50) 1.43 (0.78-4.71) 0.467
Creatinine (µmol/L)** 71.00 (57.00-80.50) 76.00 (66.25-84.75)c† 81.00 (67.75-97.75)c† <0.001
eGFRMDRD (mL/min/1.73m²) 87.04±20.83 80.20±20.25 76.42±25.36a# 0.029
Data are presented as arithmetic mean ± SD and compared by one-way ANOVA
* Log-normal distributed data are presented as geometric mean (95% CI) and compared by one-way ANOVA
** Skewed distributed data are presented as median (interquartile range) and compared by Kruskal-Wallis test
a - significantly different from the low risk group using post-hoc Tukey-Kramer test 
b - significantly different from the medium group using post-hoc Tukey-Kramer test 
c- significantly different from the low risk group using Mann-Whitney test
d- significantly different from the medium group using Mann-Whitney test
†p<0.01; ‡p<0.001; #p<0.05
Table 3: Associations between CVD risk and clinical parameters 
using Spearman’s correlation analysis
Variable CVD risk
Age (years) 0.589**
BMI (kg/m2) -0.131
WC (cm) 0.014
TC (mmol/L) 0.247**
HDL-c (mmol/L) -0.415**
LDL-c (mmol/L) 0.297**
TG (mmol/L) 0.304**
Glucose (mmol/L) 0.399**
HbA1c (%) 0.471**
Uric acid (µmol/L) 0.036
Total bilirubin (µmol/L) 0.062
HsCRP (mg/L) -0.081
Creatinine (µmol/L) 0.343**
eGFRMDRD (mL/min/1.73m²) -0.232**
Data age given as coefficients of correlation Rho (ρ)
*p<0.05, **p<0.01
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A ROC analysis was performed to test TG and creati-
nine levels discriminatory abilities regarding CVD risk 
score (low and medium vs. high). Each of them showed 
poor accuracy regarding risk scores (AUC < 0.700, Table 
5). When testing models with adjustment for confounders 
(BMI, WC, hsCRP, DBP and usage of therapies), discrim-
ination of the applied procedures was approved (AUC > 
0.750) and was considered as good (Table 5).
4  Discussion
In the current study, more males than females were clas-
sified at high-risk category of calculated UKPDS risk 
engine. Also, in our examination the UKPDS risk engine 
score classified 29.4% of individuals with DM2 at the high 
risk group. Higher risk in males was also found in other 
studies [5, 9]. Similarly, Kim et al. [22] reported 24% of sub-
jects at high CVD risk when using the UKPDS risk score 
algorithm in Korean adults with DM2. 
Ahn et al. [23] reported significant associations 
between UKPDS risk engine and carotid plaque and 
carotid artery intima-media thickness in Korean individ-
uals with DM2, showing the importance of its assessment.
Since a great number of studies reported the utility of 
UKPDS risk engine score to determine CVD risk in individ-
uals with diabetes [6, 23, 24], in our research we wanted 
to examine the associations between traditional (i.e., cre-
atinine and TG) and non-traditional (i.e., hsCRP) cardio-
metabolic markers with the UKPDS risk engine score. In 
line with this, CVD risk values highly positively correlated 
with TG and creatinine concentrations and highly nega-
tively correlated with eGFRMDRD. In multivariate regression 
analysis TG and creatinine concentration kept independ-
ent prediction for the CVD risk occurrence. According to 
R2 obtained in logistic regression analysis, the model was 
able to explain variation in CVD risk by 31.7% (Table 4). 
Moreover, a ROC analysis showed that after adjustment for 
confounders, TG and creatinine levels have good discrim-
inatory abilities (AUC > 0.750) regarding CVD risk score 
(low and medium vs. high risk), (Table 5). 
In line with our results, Bansal et al. [25] showed that 
TG levels were associated with incident cardiovascular 
Table 4: Odds ratios (OR) after univariate and multivariate logistic 
regression analysis for parameters predicting abilities regarding 
CVD risk
CVD risk
Predictors Unadjusted
OR (95% CI) p
Nagelkerke
R2
TG (mmol/L)
1.481
(1.146-1.993) 0.003 0.076
Creatinine (µmol/L)
1.034
(1.016- 1.053) <0.001 0.154
Model
Adjusted
OR (95% CI)
p Nagelkerke 
R2
TG (mmol/L)
1.703
(1.247-2.326) 0.001
Creatinine (µmol/L) 1.040(1.018- 1.063) <0.001
0.317
(for Model)
Model: confounders BMI, WC, hsCRP, DBP (all continuous variables), 
therapies (all categorical variables) and predictors (TG and creati-
nine continuous variables)
SE-Standard Error
Table 5: ROC analysis for single parameter and model discriminatory abilities regarding CVD risk 
CVD risk
Predictors AUC
(95% CI) SE
Sensitivity
(%) Specificity (%) p
TG (mmol/L) 0.621(0.528-0.713) 0.038 56.60 63.78 0.011
Creatinine (µmol/L)
0.654
(0.564-0.745) 0.046 32.08 92.91 0.001
Model
0.789
(0.719-0.859) 0.036 71.70 72.44 <0.001
Model: confounders BMI, WC, hsCRP, DBP (all continuous variables), therapies (all categorical variables) and predictors (TG and creatinine 
continuous variables)
SE-Standard Error
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events, independently of levels of other lipids, and other 
traditional risk factors.
In a recently conducted large follow-up study (median 
period of 17.7 years), in individuals with DM2, high TG in 
addition to low HDL-c levels were related to a 1.54-fold 
greater hazard ratio for CVD [26] thus pointing out the 
significance of hypertriglyceridemia as a crucial tradi-
tional CVD risk factor [27]. On the contrary, this was not 
confirmed in those subjects who were free of DM2 [27]. In 
line with that, subclinical atherosclerosis is reported to be 
predominated among patients with both DM2 and hyper-
lipidemia, rather than among DM2 individuals who did 
not have additional CVD risk factors [28].
It is widely accepted that hypertriglyceridemia is a 
metabolic hallmark that leads to a consequent events of 
further atherogenic lipid profile [29]. With progression of 
insulin resistance, the increased lipolysis of TG in adipose 
tissue occurs, thus secreting more fatty acids, leading to 
increased production of TG-rich VLDL, higher concen-
trations of more atherogenic small dense LDL, as well as 
change in HDL composition and an increased clearance of 
HDL particles [30].
Higher levels of free fatty acids in addition to insulin 
resistance further lead to endothelial dysfunction, 
reduced production of nitric oxide, vasoconstriction, 
inflammation and therefore, initiation and progression of 
atherosclerosis [30].
In addition, our results are in line with previous 
studies showing an association of high creatinine levels 
and low eGFR levels with an increased risk of CVD [31, 32].
Schneider et al. [31] in a large observational study 
showed that DM2 patients with a doubling of serum cre-
atinine levels were at an increased risk of CVD, in compar-
ison with patients with DM2 whose serum creatinine did 
not double during follow-up.
Looker et al. [33] showed that, in addition to non-tra-
ditional biomarkers, eGFR, insulin therapy and HbA1c 
need to be included for the prediction of incident CVD in 
individuals with DM2.
Non-traditional biomarkers are of questionable sig-
nificance regarding their utility in CVD risk assessment, 
since some previous studies reported the association of 
hsCRP with CV events occurrence [34, 35],  whereas some 
other studies failed to verify this observation [36, 37].
In our current study, we reported that hsCRP had no 
incremental contribution to CVD risk prediction, com-
pared to traditional risk factors. Cardoso et al. [34] sug-
gested that hsCRP may be more reliable in risk stratifica-
tion for secondary CVD prevention, but not in younger, 
lower-risk patients with DM2 treated at primary care. In 
several other studies, hsCRP was shown to be a signifcant 
predictor of CVD only among individuals without DM2 
[38].
The possible explanations for such discrepancies may 
partly be explained by different populations, sample size, 
and different follow-up periods [34].
Some of the disadvantages of the current study are 
its cross-sectional design and the relatively small sample 
size. Moreover, individuals with DM2 in our study were not 
obtained from nationally representative sample. There-
fore, longitudinal studies with nationally-representative 
sample are needed to confirm our observations. Further-
more, we were not able to measure urinary albumin excre-
tion, as kidney function marker. However, even though 
screening for chronic kidney disease based on eGFR alone 
is not recommended in the general population, it may be 
effective in high-risk subjects, such as individuals with 
DM2 [39].
Although the UKPDS risk engine represents the most 
widely used tool for CVD risk estimation, it is of impor-
tance to mention the novel risk algorithm, the VILDIA 
score for patients with DM2. The latter includes several 
new biomarkers (e.g., 25-OH vitamin D3, NT-proBNP, 
Lp-PLA2 and renin) and was shown to provide better dis-
criminatory power than the UKPDS risk engine for the 
prediction of 10-year survival. Therefore, studies in future 
are needed for the establishment of the best tool for CVD 
risk assessment in population with diabetes [40].
5  Conclusion
To the best of our knowledge, the reported herein is the 
first study that estimated CVD risk by the UKPDS risk 
engine algorithm in population with DM2 in Montenegro. 
About one third of diabetic patients (29.4%) were clas-
sified into the UKPDS risk engine high risk category. In 
addition, non-traditional parameter such as hsCRP was 
not correlated with cardiovascular risk, compared to old 
traditional risk factors such as high triglycerides and cre-
atinine levels, which suggests that old traditional markers 
must not be underestimated when examining CVD risk in 
population with diabetes.
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